ライフサイエンスコーパス: ITP

1 ITP accelerates the reaction kinetics as the ionic space

2 ITP has been largely used in traditional capillary based

3 ITP improves the LoD of LFA to the level of some lab-bas

4 ITP preconcentration accelerates the affinity reaction,

5 ITP simultaneously preconcentrates an analyte and purifi

6 ITP was more frequent among males in these subgroups.

7 ITP-enhanced LFA (ITP-LF) also shows up to 30% target ex

8 TFHs within the spleen of 8 controls and 13 ITP patients.

9 As compared with a historical cohort of 183 ITP patients, matched on the calendar year of ITP diagno

10 hout agonist stimulation was evaluated in 57 ITP patients (median age, 9.9 years).

11 e reported in 10.1% TTP, 7.1% HIT, and 25.8% ITP admissions.

12 xplored potential associations between adult ITP and various routinely administered vaccines.

13 ow-level light treatment (LLLT) to alleviate ITP in mice.

14 flame retardant mixtures: FM 550, FM 600, an ITP mixture, and a TBPP mixture.

15 ed all consecutive patients who underwent an ITP second-line treatment: Rituximab or splenectomy.

16 tion from 1 pg muL(-1) to 100 pg muL(-1) and ITP velocity over the range of 10-50 mum s(-1), and ther

17 Whilst the combination of MN and ITP did not further enhance the extent of small molecula

18 ally applicable to both cationic and anionic ITP assays and likely to a wide range of sample species.

19 The bacteria were mobilized by anionic ITP mode while cationic molecules migrate in the opposit

20 g (13.40%) for MN in combination with anodal ITP (p<0.001).

21 only in certain autoimmune diseases such as ITP.

22 The purpose of this study was to assess ITP incidence at a nationwide level (France) with recent

23 stinal or central nervous system bleeding at ITP onset was rare (<1%).

24 The IWG now proposes a consensus-based ITP-specific bleeding assessment tool (ITP-BAT) with def

25 Paper based ITP is challenged by Joule heating and evaporation becau

26 22 regulated microRNA that differed between ITP patients and controls.

27 We discuss the similarities between ITP and EFGF and describe promising possibilities to tra

28 at the latrodectin 2 gene and nearly all CHH/ITP genes include a phase 2 intron in the same position,

29 corpion and wasp venom cDNAs, as well as CHH/ITP neuropeptides, show latrodectins as derived members

30 These analyses suggest that CHH/ITP homologs are more widespread in spider venoms, and w

31 rting latrodectin's placement within the CHH/ITP superfamily.

32 w latrodectins as derived members of the CHH/ITP superfamily.

33 n of patients with newly diagnosed childhood ITP.

34 the ASH management guidelines for childhood ITP.

35 enous immunoglobulin alone developed chronic ITP less often (OR 0.39, 95% CI 0.28-0.54 and OR 0.71, 9

36 is related to bleeding phenotype in chronic ITP.

37 The following predictors of chronic ITP in children, assessed in at least 3 studies, have be

38 a-analysis to identify predictors of chronic ITP.

39 id option for treating persistent or chronic ITP in adults.

40 imab to splenectomy in persistent or chronic ITP patients.

41 well-defined cohort of 33 pediatric chronic ITP patients.

42 Thus, our data indicate that chronic ITP in childhood is a separate disease entity, dissimila

43 n immune regulation in patients with chronic ITP that may be restored in responders to thrombopoietic

44 diagnosed children and children with chronic ITP.

45 L-4 in newly diagnosed compared with chronic ITP.

46 Using this chip, we compared ITP-based surface hybridization to standard continuous f

47 (34%) of 101 patients receiving concomitant ITP medication discontinued 1 or more medication.

48 m data from the Intercontinental Cooperative ITP Study Group Registry II focusing on natural history,

49 low that opposes the ITP motion (counterflow ITP mode).

50 r the spatiotemporal behavior of the coupled ITP and affinity process, and for key figures of merit,

51 at mitigates this damage by conversion of (d)ITP to monophosphate, ITPA, has been proposed as a possi

52 triphosphates, resulting in formation of (d)ITP, can be deleterious, leading to DNA damage, mutagene

53 ntal validation of our model and demonstrate ITP-AC separation of the target from 10,000-fold more-ab

54 We demonstrate ITP-AC with 25 nt, Cy5 labeled DNA target and a DNA prob

55 a numerical and analytical model to describe ITP spacer assays, which involve low-mobility, nonfocusi

56 ciated with an observable risk of developing ITP.

57 change in the management of newly diagnosed ITP at a pediatric care tertiary care hospital in the Un

58 days 5-32) in 12 adults with newly diagnosed ITP in an outpatient setting.

59 n about practice patterns of newly diagnosed ITP in the United States.

60 311 pediatric patients with newly diagnosed ITP managed between January 1, 2007, and December 31, 20

61 the driving electric field (stop-and-diffuse ITP mode) or applying a counter flow that opposes the IT

62 f a median of 10.5 prior treatment lines for ITP (range, 6-15).

63 No associations were significant for ITP.

64 ted model enables a closed form solution for ITP-aided reaction kinetics, and reveals a new character

65 patients who have undergone splenectomy for ITP reveals significant potential risks that should be d

66 We observed that splenectomy for ITP second-line treatment was more effective than Rituxi

67 ethasone is a feasible frontline therapy for ITP.

68 ent, has become the first-line treatment for ITP; however, patients with refractory disease usually r

69 antibody [mAb]) is one of the treatments for ITP and is known to deplete B cells but may also work by

70 us, transfer of antiplatelet antibodies from ITP mothers by breastfeeding can be associated with pers

71 nalyses of mRNA and microRNA in T cells from ITP patients and controls.

72 The THD-modulated MSCs from ITP patients induced mature DCs to become tolerogenic DC

73 The study reveals the inability of MSCs from ITP patients to induce tolerogenic ability in DCs.

74 ncy; R-ITP group, 6 women who recovered from ITP before pregnancy; and 9 healthy controls.

75 ed role in ITP pathogenesis, 12 spleens from ITP patients who had been nonresponders to RTX therapy w

76 Furthermore, ITP-AC separates the target and contaminants into nondif

77 line platelet counts < 30 x 10(9)/L; 95% had ITP of > 6 months in duration.

78 groups of women: ITP group, 7 women who had ITP during pregnancy; R-ITP group, 6 women who recovered

79 luding target distribution width and height, ITP zone velocity, forward and reverse reaction constant

80 vant ITP-AC regimes, and it demonstrates how ITP greatly reduces assay time and improves column utili

81 Utilizing these unique mAbs and human ITP plasma, we find that anti-GPIbalpha, but not anti-GP

82 Importantly, ITP-DQAMmiR can be performed in a fully automated mode u

83 ammaR interaction, had been shown to improve ITP in refractory human patients.

84 increased plasma levels of interleukin-21 in ITP.

85 the secretion of antiplatelet antibodies in ITP patients.

86 e an activation of splenic CD8(+) T cells in ITP patients who did not respond to RTX and suggest thei

87 -mimetic drugs that raise platelet counts in ITP patients.

88 ea that platelet production was defective in ITP was superseded or ignored for decades, but it has no

89 plete responses (CRs) to B-cell depletion in ITP usually last for 1 year in adults, partial responses

90 the CD16(+) monocyte subset was expanded in ITP patients with low platelet counts on thrombopoietic

91 RECENT FINDINGS: In ITP, more studies are providing evidence of TPO-RA effic

92 rmine if differences in platelet function in ITP patients account for this variation in bleeding tend

93 controls, splenic TFH frequency is higher in ITP patients and correlates with germinal center and pla

94 o agonist, platelet activation was higher in ITP patients than controls.

95 We found no evidence of an increase in ITP after vaccination in the previous 6 or 12 months (ad

96 oRNA target genes significantly increased in ITP.

97 e platelet production from megakaryocytes in ITP in 1915.

98 ectiveness of the thrombopoietin mimetics in ITP.

99 We demonstrated that MSCs in ITP patients had reduced proliferative capacity and lost

100 ent description of the bleeding phenotype in ITP, and the IWG unanimously supports its adoption and v

101 be useful markers of future bleeding risk in ITP.

102 he mechanism of infection after rituximab in ITP patients.

103 potential efficacy of adjuvant rituximab in ITP.

104 e the spleen plays a well-recognized role in ITP pathogenesis, 12 spleens from ITP patients who had b

105 ociated with concurrent bleeding severity in ITP.

106 are the sites of autoantigen stimulation in ITP potentially related to a lack of control by T cells

107 of IL-21 and CD40 as therapeutic targets in ITP.

108 results point out the involvement of TFH in ITP pathophysiology and the potential interest of IL-21

109 atelet production in WAS/XLT is less than in ITP, eltrombopag has beneficial effects on platelet coun

110 vel combination of conventional therapies in ITP given over 4 weeks.

111 lecules involved in the loss of tolerance in ITP.

112 mophilus influenzae type b (Hib) vaccines in ITP patients.

113 We identified 3771 incident ITP patients.

114 dy quantified the contribution of individual ITP and TBPP isomers in four commercial flame retardant

115 mbined immunodeficient (SCID) mice to induce ITP.

116 plenocytes completely prevented CD61-induced ITP development.

117 into SCID mice with established CD61-induced ITP rescued the thrombocytopenia.

118 nsfusions affected antiplatelet CD61-induced ITP.

119 croneedles (MNs) coupled with iontophoresis (ITP) may broaden the range of drugs suitable for transde

120 Isotachophoresis (ITP) and electric field gradient focusing (EFGF) are two

121 sing electrical lysing and isotachophoresis (ITP).

122 reaction is accelerated by isotachophoresis (ITP).

123 vel technique that couples isotachophoresis (ITP) with affinity chromatography (AC) to achieve rapid,

124 We leverage isotachophoresis (ITP), an electrophoretic focusing technique, to create a

125 in the design of peak-mode isotachophoresis (ITP) experiments.

126 mple location in peak mode isotachophoresis (ITP).

127 ental study of coupling of isotachophoresis (ITP) and affinity chromatography (AC) to effect rapid, s

128 investigate integration of isotachophoresis (ITP), an electrokinetic preconcentration and extraction

129 reconcentration technique, isotachophoresis (ITP).

130 , which do not focus under isotachophoresis (ITP) unless bound to their target sequence.

131 We use isotachophoresis (ITP) to preconcentrate and co-focus target molecules and

132 Here, we use isotachophoresis (ITP), a powerful electrokinetic preconcentration and sep

133 We used isotachophoresis (ITP) coupled with an ionic spacer to both react and sepa

134 etic sample focusing using isotachophoresis (ITP) with a background signal-removal strategy that empl

135 ccelerated reactions using isotachophoresis (ITP), revealing new regimes of operation which in turn e

136 from complex samples using isotachophoresis (ITP).

137 face-based reactions using isotachophoresis (ITP).

138 ITP-enhanced LFA (ITP-LF) also shows up to 30% target extraction from 100

139 or corticosteroids for treatment of maternal ITP.

140 ty of CD8(+) T cells to activate and mediate ITP.

141 hese results indicate that antibody-mediated ITP is resistant to allogeneic platelet transfusions, wh

142 were transferred to induce antibody-mediated ITP, both CD61(+) platelet immunizations generated immun

143 ion (Bdep) therapy on CD8(+) T-cell-mediated ITP using a murine model.

144 with CD61(+) platelets, and T-cell-mediated ITP was initiated by transfer of their splenocytes into

145 s were transferred to induce T-cell-mediated ITP, transfer of allogeneic MHC-immunized splenocytes co

146 anti-GPIbalpha (but not GPIIbIIIa)-mediated ITP is often refractory to therapies targeting FcgammaR

147 eaction times of 30 min, we show that 20 min ITP hybridization can achieve 5.3-fold higher sensitivit

148 ruited into the ITP zone by higher-mobility, ITP-focused probes.

149 arameters in the optimal design of peak-mode ITP assays and highlight regimes of particular interest.

150 ituted isopropylated triaryl phosphate (mono-ITP).

151 In vivo, in a mouse ITP model we observed a short half-life of hexameric-Fc

152 In conclusion, multirefractory ITP was associated with high morbidity and mortality.

153 h a 5:1 ratio, patients with multirefractory ITP were more likely to have secondary ITP (odds ratio [

154 we included 37 patients with multirefractory ITP, defined as no response to splenectomy, rituximab, r

155 atically inhibited antibody-dependent murine ITP and successfully circumvented the inflammatory respo

156 linked to murine albumin in a passive murine ITP model.

157 erapy may be beneficial in antibody-negative ITP.

158 We here demonstrate that in RTX-nonresponder ITP patients, preferential Th1 and Tc1 T lymphocyte pola

159 However, 60% of ITP patients do not respond to RTX.

160 in FcgammaRIIB(-/-) B6 mice, amelioration of ITP was as in wild-type in all animals.

161 nofluidics, many interesting combinations of ITP and EFGF features can be achieved, yielding powerful

162 Throughout the course of ITP, 5/37 patients died, 3 with ITP (bleeding, n = 2; se

163 organ donors had a predonation diagnosis of ITP.

164 The median duration of ITP before being recognized as multirefractory was 78 mo

165 prior splenectomy, age, sex, and duration of ITP did not.

166 lytical model for spatiotemporal dynamics of ITP-AC.

167 unizations as possible triggering factors of ITP through molecular mimicry.

168 Autoantigens were not found in the GCs of ITP or controls indicating that PLNs are the sites of au

169 In both PLNs and GCs of ITP spleens, the density of T cells was significantly re

170 majority of pregnant women with a history of ITP did not require treatment, and neonatal outcomes wer

171 in that it contained TBPP isomers instead of ITP isomers.

172 idelines for the diagnosis and management of ITP and standards for terminology.

173 study was to discern whether breast milk of ITP mothers contained antiplatelet antibodies causing pe

174 of the immunoglobulin A type in the milk of ITP patients compared with the other 2 groups.

175 safe, simple, and cost-effective modality of ITP.

176 will help us understand the pathogenesis of ITP, and with appropriate safeguards, THD may benefit pa

177 of mitochondrial stress to the pathology of ITP, but also clinical potentials of LLLT as a safe, sim

178 Within PLNs of ITP, but not controls, abundant platelet glycoprotein (G

179 These results highlight the potential of ITP to increase the sensitivity of paper based LFIA unde

180 improvement of the signal-to-noise ratio of ITP-based genotypic assays.

181 astly, we demonstrate that the resolution of ITP-AC increases linearly with time and purify 25 nt tar

182 n (IVIg) and corticosteroids in treatment of ITP.

183 We demonstrate the use of ITP to preconcentrate and deliver target proteins to a s

184 eled species for application in a variety of ITP assays.

185 TP patients, matched on the calendar year of ITP diagnosis with a 5:1 ratio, patients with multirefra

186 P), the International Working Group (IWG) on ITP acknowledged that response to treatment should consi

187 P specificity of RtcB such that ATP, dGTP or ITP is used efficiently.

188 il bleeding time when applied to two passive ITP models induced by anti-CD41 antibody.

189 e (CHH) and arthropod Ion Transport Peptide (ITP) superfamily for venom expression in black widow spi

190 the expression of the ion transport peptide (ITP) to be consistent within the fifth sLN(v) and one do

191 e provide a detailed protocol for performing ITP-AC and describe the design of a buffer system to per

192 phosphate (B2IPPPP) being the most prevalent ITP isomers in both mixtures.

193 atments for immune thrombocytopenic purpura (ITP) providing durable platelet responses without contin

194 hat, in idiopathic thrombocytopenic purpura (ITP), production of platelets from megakaryocytes is def

195 a (HIT) and immune thrombocytopenic purpura (ITP).

196 eatment for immune thrombocytopenic purpura (ITP).

197 oup, 7 women who had ITP during pregnancy; R-ITP group, 6 women who recovered from ITP before pregnan

198 d-type, with or without spleens, all recover ITP with similar dynamics after IVIG (1 g/kg) treatment;

199 peutic target in the treatment of refractory ITP.

200 capture length and capture time in relevant ITP-AC regimes, and it demonstrates how ITP greatly redu

201 une causes of thrombocytopenia and secondary ITP.

202 ctory ITP were more likely to have secondary ITP (odds ratio [OR], 4.84; 95% confidence interval [CI]

203 cus target molecules and beads into a single ITP zone.

204 bridized cell-probe complexes in a two-stage ITP method.

205 t occurred with the lower-affinity substrate ITP, which could not be explained by an increase in subs

206 Transient isotachophoresis (t-ITP) was introduced in this work as an electrokineticall

207 sical CE-MS approaches, the integration of t-ITP combined with the use of a sheathless interface prov

208 We conclude that ITP patients post splenectomy are at increased risk for

209 Several reports have observed that ITP is associated with a peripheral deficiency of tolera

210 We show that ITP can achieve approximately the same sensitivity as a

211 We show that ITP is able to improve the limit of detection (LoD) of L

212 Our findings show that ITP on nitrocellulose is capable of up to a 900 fold inc

213 We show that ITP on the nitrocellulose membrane can be powered and ru

214 Our data support that ITP is a benign condition for most affected children and

215 tive incidence of sepsis was 11.1% among the ITP patients who underwent splenectomy and 10.1% among t

216 suggest similarities between FM 550 and the ITP mixture, with 2-isopropylphenyl diphenyl phosphate (

217 annel, which exhibits sharp decreases as the ITP interface moves more rapidly through the higher curr

218 the focused analyte is bound in space by the ITP interface and, upon reaction with the surface, conti

219 focusing targets that are recruited into the ITP zone by higher-mobility, ITP-focused probes.

220 rictions and on detecting the passage of the ITP interface through these constrictions.

221 Treatment of the ITP mice with 2 g/kg intravenous immunoglobulin raised t

222 arry out an experimental optimization of the ITP-based immunoassay and demonstrate a 1300-fold improv

223 or applying a counter flow that opposes the ITP motion (counterflow ITP mode).

224 enocytes, within 2 weeks after transfer, the ITP SCID mice became thrombocytopenic (< 200 x 10(9) pla

225 a major role in autoimmune thrombocytopenia (ITP).

226 approved for use in immune thrombocytopenia (ITP) after showing safety and efficacy.

227 the pathogenesis of immune thrombocytopenia (ITP) and identify a novel mechanism by which high-dose d

228 imab (RTX) to treat immune thrombocytopenia (ITP) and thrombotic thrombocytopenic purpura (TTP), resp

229 latelet function in immune thrombocytopenia (ITP) are not fully characterized.

230 T) from donors with immune thrombocytopenia (ITP) can result in significant bleeding complications in

231 Patients with immune thrombocytopenia (ITP) commonly have antiplatelet antibodies that cause th

232 role of B cells in immune thrombocytopenia (ITP) has justified the therapeutic use of anti-CD20 anti

233 reatment of primary immune thrombocytopenia (ITP) have recently emerged.

234 or managing primary immune thrombocytopenia (ITP) in adults has changed with the advent of rituximab

235 eatment options for immune thrombocytopenia (ITP) in pregnancy are limited, and evidence to guide man

236 Immune thrombocytopenia (ITP) in pregnant women can cause neonatal thrombocytopen

237 chronic/persistent immune thrombocytopenia (ITP) increased platelet counts and reduced bleeding.

238 up of children with immune thrombocytopenia (ITP) indicates that the majority undergo remission and s

239 Immune thrombocytopenia (ITP) is a bleeding disorder in which antibodies and/or T

240 Immune thrombocytopenia (ITP) is a common bleeding disorder caused primarily by a

241 Primary immune thrombocytopenia (ITP) is a disorder caused by autoantibody-mediated plate

242 Childhood immune thrombocytopenia (ITP) is a rare autoimmune bleeding disorder.

243 Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder with a complex p

244 Immune thrombocytopenia (ITP) is an autoimmune disease where platelets are destro

245 Immune thrombocytopenia (ITP) is an autoimmune disease with a complex heterogeneo

246 Immune thrombocytopenia (ITP) is an autoimmune disorder in which impaired mesench

247 Immune thrombocytopenia (ITP) is an immune-mediated acquired bleeding disorder ch

248 The epidemiology of immune thrombocytopenia (ITP) is not well known.

249 tients with primary immune thrombocytopenia (ITP) is uncertain.

250 Immune thrombocytopenia (ITP) occurs in 2 to 4/100 000 adults and results in vari

251 play a key role in immune thrombocytopenia (ITP) pathogenesis; however, little is known about T-cell

252 Immune thrombocytopenia (ITP) patients with similarly low platelet counts differ

253 7 pediatric chronic immune thrombocytopenia (ITP) patients.

254 gement of childhood immune thrombocytopenia (ITP) recommending management with observation alone when

255 Immune thrombocytopenia (ITP) results from decreased platelet production and acce

256 Immune thrombocytopenia (ITP) results from platelet destruction and production su

257 adult patients with immune thrombocytopenia (ITP) treated with rituximab to assess safety.

258 Refractory immune thrombocytopenia (ITP) was previously defined as lack of a minimum respons

259 adults with primary immune thrombocytopenia (ITP) who do not respond to, cannot tolerate, or are unwi

260 Patients with immune thrombocytopenia (ITP) who relapse after an initial trial of corticosteroi

261 adults with primary immune thrombocytopenia (ITP), addition of rituximab (RTX) to high-dose dexametha

262 utcome criteria for immune thrombocytopenia (ITP), the International Working Group (IWG) on ITP ackno

263 role of microRNA in immune thrombocytopenia (ITP), we performed genome-wide expression analyses of mR

264 d-line treatment in immune thrombocytopenia (ITP).

265 e disorder known as immune thrombocytopenia (ITP).

266 sk in patients with immune thrombocytopenia (ITP).

267 n a murine model of immune thrombocytopenia (ITP).1 The unique aspect of this protein is that it bloc

268 In conclusion, although thrombocytopenic ITP patients have higher baseline platelet activation th

269 onin (Tph1(-/-) and immune thrombocytopenic [ITP] mice).

270 based ITP-specific bleeding assessment tool (ITP-BAT) with definitions and terminology consistent wit

271 iction of the rate of surface reaction under ITP and can be used to design and optimize such assays a

272 e of antibody-secreting cells from untreated ITP spleens and from healthy tissues.

273 long-lived PC were not detected in untreated ITP spleens.

274 compared with 11 spleens from RTX-untreated ITP patients and 9 controls.

275 e pyrophosphorylase, SVEN_3972 is an unusual ITP-mannose pyrophosphorylase, and SVEN_2781 is a pyroph

276 We use ITP to focus a sample of interest and deliver a high con

277 tein release was significantly enhanced when ITP was used in combination of the soluble PMVE/MA MN ar

278 tion rates, the latter in applications where ITP is used to accelerate chemical reactions.

279 he course of ITP, 5/37 patients died, 3 with ITP (bleeding, n = 2; sepsis n = 1); 15 (40%) had at lea

280 ions with TTP; 6332 with HIT and 79 980 with ITP.

281 y and efficacy of eltrombopag in adults with ITP who had completed a previous eltrombopag study.

282 In adults with ITP, 40% of patients are complete responders at one year

283 at 1 year was significantly associated with ITP duration <1 year (P = .02) and previous transient co

284 decreased levels of IgM, are associated with ITP that is more resistant to treatment.

285 Our findings are consistent with ITP CD16(+) monocytes promoting Th1 development, which i

286 T if they receive an organ from a donor with ITP is unknown.

287 liver transplant recipients from donors with ITP compared with liver transplant recipients from donor

288 Organs from donors with ITP may be considered for transplantation, but livers sh

289 cipients of organs from deceased donors with ITP recorded in the UK Transplant Registry between 2000

290 Organs from donors with ITP resulted in 49 organ transplants (31 kidney, 14 live

291 and reducing bleeding in most patients with ITP of more than 6 months' duration.

292 Patients with ITP treated with rituximab who achieved CRs and PRs (pla

293 ere detected in the spleens of patients with ITP up to 6 months after rituximab treatment, and the PC

294 we identified a cohort of 9976 patients with ITP, 1762 of whom underwent splenectomy.

295 s-sectional study of pediatric patients with ITP.

296 te safeguards, THD may benefit patients with ITP.

297 of Treg and Th development in patients with ITP.

298 28-day phase 2 study assigned subjects with ITP of >/=3 months to once-daily oral avatrombopag (2.5,

299 er transplant recipients from donors without ITP (64% vs. 85%, p = 0.012).

300 llected milk samples from 3 groups of women: ITP group, 7 women who had ITP during pregnancy; R-ITP g